Results 231 to 240 of about 1,142,931 (269)

Role of RANK Ligand and Denosumab, a Targeted RANK Ligand Inhibitor, in Bone Health and Osteoporosis: A Review of Preclinical and Clinical Data

Clinical Therapeutics, 2012
Postmenopausal osteoporosis results from bone loss and decreased bone strength mediated by an increased rate of bone remodeling secondary to reduced estrogen levels. Remodeling cycles are initiated by osteoclasts, the formation, function, and survival of which depend on RANK ligand (RANKL).
Paul J Kostenuik, David Dempster
exaly   +3 more sources

Dysregulated Osteoprotegerin/RANK Ligand/RANK Axis in Clinical and Experimental Heart Failure [PDF]

Circulation, 2005
Background— Persistent inflammation appears to play a role in the development of heart failure (HF). Osteoprotegerin (OPG), the receptor activator of nuclear factor-κB (RANK), and RANK ligand (RANKL) are newly discovered members of the tumor necrosis factor superfamily that are critical regulators in
Thor Ueland, Erik Øie, Lars Gullestad
exaly   +3 more sources

RANK ligand inhibition with denosumab for the management of osteoporosis

Expert Opinion on Biological Therapy, 2006
Receptor activator of nuclear factor-kappaB ligand (RANKL) is a cytokine member of the tumour necrosis factor family that is the principal final mediator of osteoclastic bone resorption. It plays a major role in the pathogenesis of postmenopausal osteoporosis, as well bone loss associated with rheumatoid arthritis, metastatic cancer, multiple myeloma ...
E Michael Lewiecki
exaly   +3 more sources

The affinity of human RANK binding to its ligand RANKL

Archives of Biochemistry and Biophysics, 2009
Receptor activator of nuclear factor-kappa B (RANK) and its ligand, RANKL play critical roles in bone re-modeling, immune function, vascular disease and mammary gland development. To study the interaction of RANK and RANKL, we have expressed both extracellular domain of RANK and ectodomain of RANKL using Escherichia coli expression system.
Shu Zhou, Jingshan Ren, Zhenggang Bi
exaly   +3 more sources

Self-Assembled RANK Induces Osteoclastogenesis Ligand-Independently†

Journal of Bone and Mineral Research, 2005
Abstract By immunoprecipitation assay, we showed that mouse RANK was self-assembled through its cytoplasmic domain located at position 534–539, whose domain was different form TRAF binding domains. Moreover, overexpression experiments showed that oligomeric RANK, which was self-associated, induced osteoclastogenesis ligand-independently.
Akira Kudo
exaly   +3 more sources

Osteoprotegerin and rank ligand expression in prostate cancer

Urology, 2001
To investigate the expression of osteoprotegerin (OPG) and RANK ligand (RANKL) in human prostatic tissues. The factors regulating the increased turnover associated with prostate cancer (CaP) bone metastasis are unknown. OPG and RANKL are recently identified regulators of bone resorption and bone remodeling.Tissues from 28 patients with CaP and from 4 ...
J M, Brown, E, Corey, Z D, Lee, L D, True, T J, Yun, M, Tondravi, R L, Vessella   +6 more
openaire   +2 more sources

Clinical applications of RANK‐ligand inhibition

Internal Medicine Journal, 2009
AbstractAn enhanced rate of bone remodelling fuelled by osteoclastogenesis mediates diseases such as osteoporosis, arthritic bone destruction, Paget’s disease and malignancy‐induced bone loss. Thus, the control of osteoclastogenesis is of major clinical importance.
openaire   +2 more sources

RANK ligand and osteoprotegerin in myeloma bone disease

Blood, 2003
Myeloma bone disease is due to interactions of myeloma cells with the bone marrow microenvironment, and is associated with pathologic fractures, neurologic symptoms and hypercalcemia. Adjacent to myeloma cells, the formation and activation of osteoclasts is increased, which results in enhanced bone resorption.
Orhan, Sezer, Ulrike, Heider, Ivana, Zavrski, Christian Alexander, Kühne, Lorenz Christian, Hofbauer   +4 more
openaire   +2 more sources

Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin

Bone, 2009
Orchiectomized (ORX) rats were used to examine the extent to which their increased bone resorption and decreased bone density might relate to increases in RANKL, an essential cytokine for bone resorption.
Xiaodong, Li, Michael S, Ominsky, Marina, Stolina, Kelly S, Warmington, Zhaopo, Geng, Qing-Tian, Niu, Frank J, Asuncion, Hong-Lin, Tan, Mario, Grisanti, Denise, Dwyer, Steven, Adamu, Hua Zhu, Ke, W Scott, Simonet, Paul J, Kostenuik   +13 more
openaire   +2 more sources

New actions of rank ligand

Bone, 2012
increased fracture risk occur early after therapy is initiated, emphasising the importance of primary prevention of fracture in high-risk individuals. Most currently available guidelines for the management of GIO were developed prior to the release of FRAX® and other risk assessment tools and the approval of newer pharmacological interventions for its ...
openaire   +1 more source